SP155RENAL RESISTIVE INDEX IN LUPUS NEPHRITIS: A POTENTIAL TOOL FOR CHRONICITY ASSESSMENT

Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis

results: The injection of sema3A into young mice (at week 12) before the onset of disease (the prevention group) delayed the appearance of proteinuria. Here, the median time to severe proteinuria was 110 days, 95% CI: 88–131. However, in mice in which the empty vector was injected, the median time to severe proteinuria was 63 days, 95% CI: 0–139. sema3A treatment, significantly reduced renal da...

The prognosis of lupus nephritis in children

Introduction: Lupus nephritis is a systemic disease which affects different organs. The present study was designed to review lupus nephritis, in children its outcome and the related factors. Methods: We reviewed 48 children with lupus nephritis. Clinical and epidemiological features were studied. The patients’ outcomes and related factors were analyzed. Patient and renal survival rate were ca...

Serum alpha–actinin antibody status in systemic lupus erythematosus and its potential in the diagnosis of lupus nephritis

Background: In lupus nephritis (LN), deposition of pathogenic autoantibodies in the glomeruli is mediated via cross-reactivity with alpha-actinin. Association of serum alpha-actinin antibody (AαA) with LN has been shown in a few studies but the results are controversial. Methods: Eighty patients into entered the study. The diagnosis of SLE was confirmed according to the American College of Rheu...

Urinary Angiostatin - a novel marker of renal pathology chronicity in lupus nephritis

Interferon (IFN)-λ is a potential mediator in lupus nephritis

OBJECTIVES Interferon (IFN)-α is thought to be central in the pathogenesis for lupus nephritis (LN) and recent studies also indicate a role for IFNλ. Little is known about these cytokines in the context of treatment response. We studied levels of IFNα and IFNλ in patients with LN in association with clinical and histological response (HR) to treatment. METHODS Fifty-six patients with active L...